Zhaoyang Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Zhaoyang Yang has a total of 135 co-authors. Here are the top co-authors by number of shared publications:
- Xiao-Guang Li
Department of Neurobiology, School of Basic Medical Sciences, Capital Medical University, Beijing, China
29 shared publications Wen Zhao
Department of Neurobiology, School of Basic Medical Sciences, Capital Medical University, 100069 Beijing, China
18 shared publicationsPeng Hao
Department of Neurobiology, School of Basic Medical Sciences, Capital Medical University, 100069 Beijing, China
16 shared publicationsYudan Gao
Department of Neurobiology, School of Basic Medical Sciences, Capital Medical University, 100069 Beijing, China
14 shared publications- Hongmei Duan
Department of Neurobiology, School of Basic Medical Sciences, Capital Medical University, Beijing 100069, China
12 shared publications Hongmei Duan
Department of Neurobiology, School of Basic Medical Sciences, Capital Medical University, 100069 Beijing, China
11 shared publications
Latest Publications
- Open Access
- 1 November 2026
- Published by KEAI Publishing in Bioactive Materials
- Vol. 65, 181-197
Intravitreal delivery of NGF-chitosan hydrogel confers retinal ganglion cell protection and visual function recovery in experimental glaucoma
Glaucoma is one of the leading causes of irreversible blindness, and lowering intraocular pressure alone is insufficient to rescue lost retinal ganglion cells (RGCs) or restore visual function. In this study, we intravitreally injected a liquid chitosan gel loaded with nerve growth factor (NGF), previously developed by our group, into the vitreous body of rats with ocular hypertension-induced glaucoma. Using a combination of techniques--including multiplex immunofluorescence staining, TUNEL staining, CTB tracing, Western blotting, visual electrophysiology, and behavioral assessments--we demonstrated that, compared with the lesion control (LC) group, the NGF-chitosan hydrogel significantly enhanced RGC survival following glaucomatous injury (by approximately 27%), preserved dendritic architecture and long-distance axonal projections, and promoted recovery of visual function. Mechanistically, treatment with the NGF-chitosan hydrogel upregulated the expression of NGF and its high-affinity receptor, tropomyosin receptor kinase A (TrkA), in the retina. In addition, it suppressed retinal glial activation and enhanced mammalian target of rapamycin (mTOR) signaling, collectively contributing to RGC protection and repair. Notably, we further observed activation of Nestin+ neural stem cells in the ciliary body region, along with their differentiation into BrdU+/Brn3a+ neuron-like cells; the precise mechanisms underlying this phenomenon warrant further investigation. In conclusion, intravitreal delivery of NGF-chitosan hydrogel provides novel mechanistic insights and represents a promising therapeutic strategy for the treatment of glaucoma.
- 1 November 2026
- Published by KEAI Publishing in Bioactive Materials
- Vol. 65, 181-197
Open AccessIntravitreal delivery of NGF-chitosan hydrogel confers retinal ganglion cell protection and visual function recovery in experimental glaucoma
Glaucoma is one of the leading causes of irreversible blindness, and lowering intraocular pressure alone is insufficient to rescue lost retinal ganglion cells (RGCs) or restore visual function. In this study, we intravitreally injected a liquid chitosan gel loaded with nerve growth factor (NGF), previously developed by our group, into the vitreous body of rats with ocular hypertension-induced glaucoma. Using a combination of techniques--including multiplex immunofluorescence staining, TUNEL staining, CTB tracing, Western blotting, visual electrophysiology, and behavioral assessments--we demonstrated that, compared with the lesion control (LC) group, the NGF-chitosan hydrogel significantly enhanced RGC survival following glaucomatous injury (by approximately 27%), preserved dendritic architecture and long-distance axonal projections, and promoted recovery of visual function. Mechanistically, treatment with the NGF-chitosan hydrogel upregulated the expression of NGF and its high-affinity receptor, tropomyosin receptor kinase A (TrkA), in the retina. In addition, it suppressed retinal glial activation and enhanced mammalian target of rapamycin (mTOR) signaling, collectively contributing to RGC protection and repair. Notably, we further observed activation of Nestin+ neural stem cells in the ciliary body region, along with their differentiation into BrdU+/Brn3a+ neuron-like cells; the precise mechanisms underlying this phenomenon warrant further investigation. In conclusion, intravitreal delivery of NGF-chitosan hydrogel provides novel mechanistic insights and represents a promising therapeutic strategy for the treatment of glaucoma.
- Open Access
- 17 July 2026
- Published by Elsevier in Neurobiology of Disease
- Vol. 228, 107540
Transient ocular hypertension drives delayed and IOP-independent retinal neurodegeneration
- 17 July 2026
- Published by Elsevier in Neurobiology of Disease
- Vol. 228, 107540
Open AccessTransient ocular hypertension drives delayed and IOP-independent retinal neurodegeneration
- Open Access
- 10 June 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (6) , 1316
BDNF-Hyaluronic Acid Hydrogel Promotes Neuronal Differentiation of Neural Stem Cells in Aβ-Induced Injury and 5×FAD Mice
Objectives: Alzheimer’s disease (AD) is associated with impaired adult hippocampal neurogenesis (AHN). This study aimed to establish an in vitro model of Aβ1–42 oligomer-damaged neural stem cells (NSCs) and to employ the 5×FAD mouse model of AD in vivo, and to evaluate the therapeutic effects of brain-derived neurotrophic factor-loaded hyaluronic acid hydrogel (BDNF-HA gel) on AHN. Methods: In vitro, BDNF-HA gel was co-cultured with Aβ1–42 oligomer-impaired NSC spheres and evaluate NSC proliferation, migration, and differentiation. In vivo, BDNF-HA gel was infused intracerebroventricularly into 5×FAD mice. Using BrdU labeling, immunofluorescence, anterograde transsynaptic viral tracing, and behavioral tests, we assessed the effects of BDNF-HA gel on adult neurogenesis, newborn neuron integration into memory circuits, and cognitive function. Results: In vitro, BDNF-HA gel attenuated Aβ1–42-induced NSC apoptosis, restored proliferation and migration, promoted differentiation into neuroblasts, newborn neurons, and oligodendrocytes, and alleviated mitochondrial depolarization and loss of mitochondrial mass. In vivo, despite the absence of significant Aβ plaques reduction in 5×FAD mice, BDNF-HA gel markedly enhanced NSC proliferation and neurogenesis in the subventricular zone (SVZ) and subgranular zone (SGZ). Behavioral tests further revealed significant improvements in object recognition, spatial working memory, and spatial reference memory. Conclusions: BDNF-HA gel can effectively counteract the toxic microenvironment induced by Aβ oligomers, promoting NSC proliferation, migration, and differentiation into neurons. Without altering the Aβ burden, it significantly enhances adult neurogenesis and rescues cognitive deficits in AD mice.
- 10 June 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (6) , 1316
Open AccessBDNF-Hyaluronic Acid Hydrogel Promotes Neuronal Differentiation of Neural Stem Cells in Aβ-Induced Injury and 5×FAD Mice
Objectives: Alzheimer’s disease (AD) is associated with impaired adult hippocampal neurogenesis (AHN). This study aimed to establish an in vitro model of Aβ1–42 oligomer-damaged neural stem cells (NSCs) and to employ the 5×FAD mouse model of AD in vivo, and to evaluate the therapeutic effects of brain-derived neurotrophic factor-loaded hyaluronic acid hydrogel (BDNF-HA gel) on AHN. Methods: In vitro, BDNF-HA gel was co-cultured with Aβ1–42 oligomer-impaired NSC spheres and evaluate NSC proliferation, migration, and differentiation. In vivo, BDNF-HA gel was infused intracerebroventricularly into 5×FAD mice. Using BrdU labeling, immunofluorescence, anterograde transsynaptic viral tracing, and behavioral tests, we assessed the effects of BDNF-HA gel on adult neurogenesis, newborn neuron integration into memory circuits, and cognitive function. Results: In vitro, BDNF-HA gel attenuated Aβ1–42-induced NSC apoptosis, restored proliferation and migration, promoted differentiation into neuroblasts, newborn neurons, and oligodendrocytes, and alleviated mitochondrial depolarization and loss of mitochondrial mass. In vivo, despite the absence of significant Aβ plaques reduction in 5×FAD mice, BDNF-HA gel markedly enhanced NSC proliferation and neurogenesis in the subventricular zone (SVZ) and subgranular zone (SGZ). Behavioral tests further revealed significant improvements in object recognition, spatial working memory, and spatial reference memory. Conclusions: BDNF-HA gel can effectively counteract the toxic microenvironment induced by Aβ oligomers, promoting NSC proliferation, migration, and differentiation into neurons. Without altering the Aβ burden, it significantly enhances adult neurogenesis and rescues cognitive deficits in AD mice.
- Open Access
- 27 January 2026
- Published by Wolters Kluwer Health in Neural Regeneration Research
- Vol. 21 (9) , 4290-4296
Biomaterial gels drive endogenous neurogenesis to support functional recovery after adult traumatic cortical injury
Activation and neuronal differentiation of endogenous neural stem/progenitor cells within the hippocampal neurogenic niche (a neurogenic region) of the adult mammalian brain are considered potential bases for restoration of cognitive and memory functions. However, following traumatic cortical brain injury (i.e., injuries in a non-neurogenic region), the local microenvironment becomes hostile due to the presence of inhibitory factors such as inflammation, edema, and hypoxic-ischemic stress. These conditions hinder the migration and subsequent neuronal differentiation of activated neural stem/progenitor cells into the injured cortex. Numerous recent studies have confirmed that biomaterials can improve the microenvironment of the injured area and promote nerve regeneration. In this study, we report the findings obtained by injecting a biodegradable chitosan-gelatin-collagen gel into the cortical lesion area. We observed that the chitosan-gelatin-collagen gel established a permissive microenvironment for neural repair by suppressing inflammation and scar infiltration while promoting neovascularization. Thus, it enabled activated endogenous "seed" cells, i.e., neural stem/progenitor cells, to migrate into the cortical lesion area and generate new neurons and thereby facilitate functional recovery. These findings represent a novel biomaterial-based therapeutic strategy for the treatment of traumatic cortical brain injury, stroke, and other neurological disorders.
- 27 January 2026
- Published by Wolters Kluwer Health in Neural Regeneration Research
- Vol. 21 (9) , 4290-4296
Open AccessBiomaterial gels drive endogenous neurogenesis to support functional recovery after adult traumatic cortical injury
Activation and neuronal differentiation of endogenous neural stem/progenitor cells within the hippocampal neurogenic niche (a neurogenic region) of the adult mammalian brain are considered potential bases for restoration of cognitive and memory functions. However, following traumatic cortical brain injury (i.e., injuries in a non-neurogenic region), the local microenvironment becomes hostile due to the presence of inhibitory factors such as inflammation, edema, and hypoxic-ischemic stress. These conditions hinder the migration and subsequent neuronal differentiation of activated neural stem/progenitor cells into the injured cortex. Numerous recent studies have confirmed that biomaterials can improve the microenvironment of the injured area and promote nerve regeneration. In this study, we report the findings obtained by injecting a biodegradable chitosan-gelatin-collagen gel into the cortical lesion area. We observed that the chitosan-gelatin-collagen gel established a permissive microenvironment for neural repair by suppressing inflammation and scar infiltration while promoting neovascularization. Thus, it enabled activated endogenous "seed" cells, i.e., neural stem/progenitor cells, to migrate into the cortical lesion area and generate new neurons and thereby facilitate functional recovery. These findings represent a novel biomaterial-based therapeutic strategy for the treatment of traumatic cortical brain injury, stroke, and other neurological disorders.
- Open Access
- 25 November 2025
- Published by Wolters Kluwer Health in Neural Regeneration Research
- Vol. 21 (8) , 3696-3705
Basic fibroblast growth factor sustained-release system promotes neurogenesis and tissue repair after spinal cord injury
Export Spinal cord injury is accompanied by a substantial loss of neurons. Cell replacement therapy improves motor and sensory dysfunction by replacing dead neurons, and endogenous neurogenesis is an important cell replacement source. Stimulating endogenous neurogenesis is therefore a viable approach for treating spinal cord injury. Given that basic fibroblast growth factor is a potent inducer of neurogenesis, we developed a sustained-release system of basic fibroblast growth factor-chitosan to enhance tissue repair in spinal cord injury. In the present study, we isolated neural stem cells from the spinal cords of neonatal rats and used single-cell RNA sequencing to trace the complete process of neurogenesis under ex vivo culture conditions. Under the influence of basic fibroblast growth factor-chitosan, neural stem cells were able to transition from a quiescent state to an activated state and subsequently differentiate into neuronal precursor cells and immature neurons. Additionally, basic fibroblast growth factor-chitosan significantly enhanced neural stem cell proliferation in vitro and promoted neuronal generation. Subsequent in vivo experiments confirmed the therapeutic efficacy of basic fibroblast growth factor-chitosan in spinal cord injury, demonstrating enhanced neurogenesis and tissue repair.
- 25 November 2025
- Published by Wolters Kluwer Health in Neural Regeneration Research
- Vol. 21 (8) , 3696-3705
Open AccessBasic fibroblast growth factor sustained-release system promotes neurogenesis and tissue repair after spinal cord injury
Export Spinal cord injury is accompanied by a substantial loss of neurons. Cell replacement therapy improves motor and sensory dysfunction by replacing dead neurons, and endogenous neurogenesis is an important cell replacement source. Stimulating endogenous neurogenesis is therefore a viable approach for treating spinal cord injury. Given that basic fibroblast growth factor is a potent inducer of neurogenesis, we developed a sustained-release system of basic fibroblast growth factor-chitosan to enhance tissue repair in spinal cord injury. In the present study, we isolated neural stem cells from the spinal cords of neonatal rats and used single-cell RNA sequencing to trace the complete process of neurogenesis under ex vivo culture conditions. Under the influence of basic fibroblast growth factor-chitosan, neural stem cells were able to transition from a quiescent state to an activated state and subsequently differentiate into neuronal precursor cells and immature neurons. Additionally, basic fibroblast growth factor-chitosan significantly enhanced neural stem cell proliferation in vitro and promoted neuronal generation. Subsequent in vivo experiments confirmed the therapeutic efficacy of basic fibroblast growth factor-chitosan in spinal cord injury, demonstrating enhanced neurogenesis and tissue repair.
- 27 May 2025
- Published by Springer Nature in Science China Life Sciences
- Vol. 68 (8) , 2393-2407
Effects of NGF-chitosan on alleviating secondary degeneration and repairing primary degeneration after expanded partial optic nerve transection
Optic neuropathy is one of the main causes of irreversible blindness in the world, and there is no effective treatment in clinic. Both primary degeneration and secondary degeneration play an important role in the injury caused by optic neuropathy. Partial optic nerve transection (PONT) model can be used to study these two kinds of degeneration simultaneously. However, there is currently no measure that can effectively intervene in both types of injuries concurrently. Here, we constructed an expanded partial optic nerve transection (EPONT) model. Nerve growth factor (NGF)-chitosan locally implanted into the injured area could simultaneously intervene in the secondary and primary degeneration, not only protecting the ventral part of the injured optic nerve, but also promoting the regeneration of the dorsal part. Visual functions, including pupillary light reflex and depth perception, were also well preserved. NGF-chitosan exerted biological effects by enhancing the expression of NGF and tyrosine kinase A (TrkA) in the optic nerve and retinal ganglion cells (RGCs). Furthermore, NGF-chitosan played a protective and repairing role by inhibiting the activation of microglia in the ventral area of the injured optic nerve and increasing the expression of mammalian target of rapamycin (mTOR) in RGCs. Our results demonstrate that the local use of NGF-chitosan in the injured area effectively repaired the optic nerve, which provides a new measure for the clinical treatment of optic nerve injury.
- 27 May 2025
- Published by Springer Nature in Science China Life Sciences
- Vol. 68 (8) , 2393-2407
Effects of NGF-chitosan on alleviating secondary degeneration and repairing primary degeneration after expanded partial optic nerve transection
Optic neuropathy is one of the main causes of irreversible blindness in the world, and there is no effective treatment in clinic. Both primary degeneration and secondary degeneration play an important role in the injury caused by optic neuropathy. Partial optic nerve transection (PONT) model can be used to study these two kinds of degeneration simultaneously. However, there is currently no measure that can effectively intervene in both types of injuries concurrently. Here, we constructed an expanded partial optic nerve transection (EPONT) model. Nerve growth factor (NGF)-chitosan locally implanted into the injured area could simultaneously intervene in the secondary and primary degeneration, not only protecting the ventral part of the injured optic nerve, but also promoting the regeneration of the dorsal part. Visual functions, including pupillary light reflex and depth perception, were also well preserved. NGF-chitosan exerted biological effects by enhancing the expression of NGF and tyrosine kinase A (TrkA) in the optic nerve and retinal ganglion cells (RGCs). Furthermore, NGF-chitosan played a protective and repairing role by inhibiting the activation of microglia in the ventral area of the injured optic nerve and increasing the expression of mammalian target of rapamycin (mTOR) in RGCs. Our results demonstrate that the local use of NGF-chitosan in the injured area effectively repaired the optic nerve, which provides a new measure for the clinical treatment of optic nerve injury.
- Open Access
- 3 June 2024
- Published by Wolters Kluwer Health in Neural Regeneration Research
- Vol. 20 (10) , 2923-2937
Activation of adult endogenous neurogenesis by a hyaluronic acid collagen gel containing basic fibroblast growth factor promotes remodeling and functional recovery of the injured cerebral cortex
JOURNAL/nrgr/04.03/01300535-202510000-00024/figure1/v/2026-04-25T153616Z/r/image-tiff The presence of endogenous neural stem/progenitor cells in the adult mammalian brain suggests that the central nervous system can be repaired and regenerated after injury. However, whether it is possible to stimulate neurogenesis and reconstruct cortical layers II to VI in non-neurogenic regions, such as the cortex, remains unknown. In this study, we implanted a hyaluronic acid collagen gel loaded with basic fibroblast growth factor into the motor cortex immediately following traumatic injury. Our findings reveal that this gel effectively stimulated the proliferation and migration of endogenous neural stem/progenitor cells, as well as their differentiation into mature and functionally integrated neurons. Importantly, these new neurons reconstructed the architecture of cortical layers II to VI, integrated into the existing neural circuitry, and ultimately led to improved brain function. These findings offer novel insight into potential clinical treatments for traumatic cerebral cortex injuries.
- 3 June 2024
- Published by Wolters Kluwer Health in Neural Regeneration Research
- Vol. 20 (10) , 2923-2937
Open AccessActivation of adult endogenous neurogenesis by a hyaluronic acid collagen gel containing basic fibroblast growth factor promotes remodeling and functional recovery of the injured cerebral cortex
JOURNAL/nrgr/04.03/01300535-202510000-00024/figure1/v/2026-04-25T153616Z/r/image-tiff The presence of endogenous neural stem/progenitor cells in the adult mammalian brain suggests that the central nervous system can be repaired and regenerated after injury. However, whether it is possible to stimulate neurogenesis and reconstruct cortical layers II to VI in non-neurogenic regions, such as the cortex, remains unknown. In this study, we implanted a hyaluronic acid collagen gel loaded with basic fibroblast growth factor into the motor cortex immediately following traumatic injury. Our findings reveal that this gel effectively stimulated the proliferation and migration of endogenous neural stem/progenitor cells, as well as their differentiation into mature and functionally integrated neurons. Importantly, these new neurons reconstructed the architecture of cortical layers II to VI, integrated into the existing neural circuitry, and ultimately led to improved brain function. These findings offer novel insight into potential clinical treatments for traumatic cerebral cortex injuries.
- Open Access
- 1 April 2024
- Published by Wolters Kluwer Health in Neural Regeneration Research
- Vol. 19 (12) , 2588-2601
A core scientific problem in the treatment of central nervous system diseases: newborn neurons
It has long been asserted that failure to recover from central nervous system diseases is due to the system’s intricate structure and the regenerative incapacity of adult neurons. Yet over recent decades, numerous studies have established that endogenous neurogenesis occurs in the adult central nervous system, including humans’. This has challenged the long-held scientific consensus that the number of adult neurons remains constant, and that new central nervous system neurons cannot be created or renewed. Herein, we present a comprehensive overview of the alterations and regulatory mechanisms of endogenous neurogenesis following central nervous system injury, and describe novel treatment strategies that target endogenous neurogenesis and newborn neurons in the treatment of central nervous system injury. Central nervous system injury frequently results in alterations of endogenous neurogenesis, encompassing the activation, proliferation, ectopic migration, differentiation, and functional integration of endogenous neural stem cells. Because of the unfavorable local microenvironment, most activated neural stem cells differentiate into glial cells rather than neurons. Consequently, the injury-induced endogenous neurogenesis response is inadequate for repairing impaired neural function. Scientists have attempted to enhance endogenous neurogenesis using various strategies, including using neurotrophic factors, bioactive materials, and cell reprogramming techniques. Used alone or in combination, these therapeutic strategies can promote targeted migration of neural stem cells to an injured area, ensure their survival and differentiation into mature functional neurons, and facilitate their integration into the neural circuit. Thus can integration replenish lost neurons after central nervous system injury, by improving the local microenvironment. By regulating each phase of endogenous neurogenesis, endogenous neural stem cells can be harnessed to promote effective regeneration of newborn neurons. This offers a novel approach for treating central nervous system injury.
- 1 April 2024
- Published by Wolters Kluwer Health in Neural Regeneration Research
- Vol. 19 (12) , 2588-2601
Open AccessA core scientific problem in the treatment of central nervous system diseases: newborn neurons
It has long been asserted that failure to recover from central nervous system diseases is due to the system’s intricate structure and the regenerative incapacity of adult neurons. Yet over recent decades, numerous studies have established that endogenous neurogenesis occurs in the adult central nervous system, including humans’. This has challenged the long-held scientific consensus that the number of adult neurons remains constant, and that new central nervous system neurons cannot be created or renewed. Herein, we present a comprehensive overview of the alterations and regulatory mechanisms of endogenous neurogenesis following central nervous system injury, and describe novel treatment strategies that target endogenous neurogenesis and newborn neurons in the treatment of central nervous system injury. Central nervous system injury frequently results in alterations of endogenous neurogenesis, encompassing the activation, proliferation, ectopic migration, differentiation, and functional integration of endogenous neural stem cells. Because of the unfavorable local microenvironment, most activated neural stem cells differentiate into glial cells rather than neurons. Consequently, the injury-induced endogenous neurogenesis response is inadequate for repairing impaired neural function. Scientists have attempted to enhance endogenous neurogenesis using various strategies, including using neurotrophic factors, bioactive materials, and cell reprogramming techniques. Used alone or in combination, these therapeutic strategies can promote targeted migration of neural stem cells to an injured area, ensure their survival and differentiation into mature functional neurons, and facilitate their integration into the neural circuit. Thus can integration replenish lost neurons after central nervous system injury, by improving the local microenvironment. By regulating each phase of endogenous neurogenesis, endogenous neural stem cells can be harnessed to promote effective regeneration of newborn neurons. This offers a novel approach for treating central nervous system injury.
- Open Access
- 20 July 2023
- Published by Medknow in Neural Regeneration Research
- Vol. 19 (3) , 636-641
Visualizing Wallerian degeneration in the corticospinal tract after sensorimotor cortex ischemia in mice
JOURNAL/nrgr/04.03/01300535-202403000-00039/inline-graphic1/v/2023-09-27T141015Z/r/image-tiff Stroke can cause Wallerian degeneration in regions outside of the brain, particularly in the corticospinal tract. To investigate the fate of major glial cells and axons within affected areas of the corticospinal tract following stroke, we induced photochemical infarction of the sensorimotor cortex leading to Wallerian degeneration along the full extent of the corticospinal tract. We first used a routine, sensitive marker of axonal injury, amyloid precursor protein, to examine Wallerian degeneration of the corticospinal tract. An antibody to amyloid precursor protein mapped exclusively to proximal axonal segments within the ischemic cortex, with no positive signal in distal parts of the corticospinal tract, at all time points. To improve visualization of Wallerian degeneration, we next utilized an orthograde virus that expresses green fluorescent protein to label the corticospinal tract and then quantitatively evaluated green fluorescent protein-expressing axons. Using this approach, we found that axonal degeneration began on day 3 post-stroke and was almost complete by 7 days after stroke. In addition, microglia mobilized and activated early, from day 7 after stroke, but did not maintain a phagocytic state over time. Meanwhile, astrocytes showed relatively delayed mobilization and a moderate response to Wallerian degeneration. Moreover, no anterograde degeneration of spinal anterior horn cells was observed in response to Wallerian degeneration of the corticospinal tract. In conclusion, our data provide evidence for dynamic, pathogenic spatiotemporal changes in major cellular components of the corticospinal tract during Wallerian degeneration.
- 20 July 2023
- Published by Medknow in Neural Regeneration Research
- Vol. 19 (3) , 636-641
Open AccessVisualizing Wallerian degeneration in the corticospinal tract after sensorimotor cortex ischemia in mice
JOURNAL/nrgr/04.03/01300535-202403000-00039/inline-graphic1/v/2023-09-27T141015Z/r/image-tiff Stroke can cause Wallerian degeneration in regions outside of the brain, particularly in the corticospinal tract. To investigate the fate of major glial cells and axons within affected areas of the corticospinal tract following stroke, we induced photochemical infarction of the sensorimotor cortex leading to Wallerian degeneration along the full extent of the corticospinal tract. We first used a routine, sensitive marker of axonal injury, amyloid precursor protein, to examine Wallerian degeneration of the corticospinal tract. An antibody to amyloid precursor protein mapped exclusively to proximal axonal segments within the ischemic cortex, with no positive signal in distal parts of the corticospinal tract, at all time points. To improve visualization of Wallerian degeneration, we next utilized an orthograde virus that expresses green fluorescent protein to label the corticospinal tract and then quantitatively evaluated green fluorescent protein-expressing axons. Using this approach, we found that axonal degeneration began on day 3 post-stroke and was almost complete by 7 days after stroke. In addition, microglia mobilized and activated early, from day 7 after stroke, but did not maintain a phagocytic state over time. Meanwhile, astrocytes showed relatively delayed mobilization and a moderate response to Wallerian degeneration. Moreover, no anterograde degeneration of spinal anterior horn cells was observed in response to Wallerian degeneration of the corticospinal tract. In conclusion, our data provide evidence for dynamic, pathogenic spatiotemporal changes in major cellular components of the corticospinal tract during Wallerian degeneration.
- Open Access
- 20 July 2023
- Published by Medknow in Neural Regeneration Research
- Vol. 19 (3) , 680-686
Chitosan-based thermosensitive hydrogel with long-term release of murine nerve growth factor for neurotrophic keratopathy
JOURNAL/nrgr/04.03/01300535-202403000-00045/inline-graphic1/v/2023-09-27T141015Z/r/image-tiff Neurotrophic keratopathy is a persistent defect of the corneal epithelium, with or without stromal ulceration, due to corneal nerve deficiency caused by a variety of etiologies. The treatment options for neurotrophic keratopathy are limited. In this study, an ophthalmic solution was constructed from a chitosan-based thermosensitive hydrogel with long-term release of murine nerve growth factor (CTH-mNGF). Its effectiveness was evaluated in corneal denervation (CD) mice and patients with neurotrophic keratopathy. In the preclinical setting, CTH-mNGF was assessed in a murine corneal denervation model. CTH-mNGF was transparent, thermosensitive, and ensured sustained release of mNGF for over 20 hours on the ocular surface, maintaining the local mNGF concentration around 1300 pg/mL in vivo. Corneal denervation mice treated with CTH-mNGF for 10 days showed a significant increase in corneal nerve area and total corneal nerve length compared with non-treated and CTH treated mice. A subsequent clinical trial of CTH-mNGF was conducted in patients with stage 2 or 3 neurotrophic keratopathy. Patients received topical CTH-mNGF twice daily for 8 weeks. Fluorescein sodium images, Schirmer’s test, intraocular pressure, Cochet-Bonnet corneal perception test, and best corrected visual acuity were evaluated. In total, six patients (total of seven eyes) diagnosed with neurotrophic keratopathy were enrolled. After 8 weeks of CTH-mNGF treatment, all participants showed a decreased area of corneal epithelial defect, as stained by fluorescence. Overall, six out of seven eyes had fluorescence staining scores < 5. Moreover, best corrected visual acuity, intraocular pressure, Schirmer’s test and Cochet-Bonnet corneal perception test results showed no significant improvement. An increase in corneal nerve density was observed by in vivo confocal microscopy after 8 weeks of CTH-mNGF treatment in three out of seven eyes. This study demonstrates that CTH-mNGF is transparent, thermosensitive, and has sustained-release properties. Its effectiveness in healing corneal epithelial defects in all eyes with neurotrophic keratopathy suggests CTH-mNGF has promising application prospects in the treatment of neurotrophic keratopathy, being convenient and cost effective.
- 20 July 2023
- Published by Medknow in Neural Regeneration Research
- Vol. 19 (3) , 680-686
Open AccessChitosan-based thermosensitive hydrogel with long-term release of murine nerve growth factor for neurotrophic keratopathy
JOURNAL/nrgr/04.03/01300535-202403000-00045/inline-graphic1/v/2023-09-27T141015Z/r/image-tiff Neurotrophic keratopathy is a persistent defect of the corneal epithelium, with or without stromal ulceration, due to corneal nerve deficiency caused by a variety of etiologies. The treatment options for neurotrophic keratopathy are limited. In this study, an ophthalmic solution was constructed from a chitosan-based thermosensitive hydrogel with long-term release of murine nerve growth factor (CTH-mNGF). Its effectiveness was evaluated in corneal denervation (CD) mice and patients with neurotrophic keratopathy. In the preclinical setting, CTH-mNGF was assessed in a murine corneal denervation model. CTH-mNGF was transparent, thermosensitive, and ensured sustained release of mNGF for over 20 hours on the ocular surface, maintaining the local mNGF concentration around 1300 pg/mL in vivo. Corneal denervation mice treated with CTH-mNGF for 10 days showed a significant increase in corneal nerve area and total corneal nerve length compared with non-treated and CTH treated mice. A subsequent clinical trial of CTH-mNGF was conducted in patients with stage 2 or 3 neurotrophic keratopathy. Patients received topical CTH-mNGF twice daily for 8 weeks. Fluorescein sodium images, Schirmer’s test, intraocular pressure, Cochet-Bonnet corneal perception test, and best corrected visual acuity were evaluated. In total, six patients (total of seven eyes) diagnosed with neurotrophic keratopathy were enrolled. After 8 weeks of CTH-mNGF treatment, all participants showed a decreased area of corneal epithelial defect, as stained by fluorescence. Overall, six out of seven eyes had fluorescence staining scores < 5. Moreover, best corrected visual acuity, intraocular pressure, Schirmer’s test and Cochet-Bonnet corneal perception test results showed no significant improvement. An increase in corneal nerve density was observed by in vivo confocal microscopy after 8 weeks of CTH-mNGF treatment in three out of seven eyes. This study demonstrates that CTH-mNGF is transparent, thermosensitive, and has sustained-release properties. Its effectiveness in healing corneal epithelial defects in all eyes with neurotrophic keratopathy suggests CTH-mNGF has promising application prospects in the treatment of neurotrophic keratopathy, being convenient and cost effective.